Hoʻolauna
ʻO Tirzepatide, i hoʻomohala ʻia e Eli Lilly, he lāʻau peptide hou e hōʻike ana i kahi milestone i ka mālama ʻana i ka maʻi diabetes type 2 a me ka momona. ʻAʻole like me ka GLP-1 (glucagon-like peptide-1) agonists, hana ʻo Tirzepatideʻelua GIP (glucose-dependent insulinotropic polypeptide)aNā mea loaʻa GLP-1, loaa iaia ka inoa o aʻelua agonist hoʻokipa. Hiki i kēia ʻano hana ʻelua ke hana maikaʻi loa i ka hoʻoponopono ʻana i ka glucose koko a me ka hōʻemi ʻana i ke kaumaha o ke kino, ʻoi aku hoʻi no nā poʻe maʻi me ka maʻi diabetes type 2 a me ka momona.
Mechanism of Action
-
ʻO ka hoʻonā ʻana o ka mea hoʻokipa GIP: Hoʻonui i ka huna ʻana o ka insulin a hoʻomaikaʻi i ka hoʻomanawanui glucose.
-
ʻO ka hoʻoulu ʻana o ka mea hoʻokipa GLP-1: Hoʻoikaika i ka hoʻokuʻu ʻana o ka insulin, hoʻopaʻa i ka huna ʻana o ka glucagon, a hoʻolohi i ka hemo ʻana o ka ʻōpū.
-
ʻO ka hui ʻelua: Hāʻawi i ka mana glycemic maikaʻi a me ka hoʻohaʻahaʻa kaumaha nui.
Ka Ikepili Ikepili
1. ʻOi aku ma mua o nā hoʻāʻo (ʻano maʻi diabetes type 2)
Ma waena o nā mea he nuiSURPASS na hoao ana, Tirzepatide ma mua o ka insulin a me Semaglutide i nā hopena glycemic a me ke kaumaha.
| Hui Hoomanawanui | Kau | Avg. Hoemi HbA1c | Avg. Paona Paona |
|---|---|---|---|
| ʻAno maʻi diabetes 2 | 5 mg | -2.0% | -7.0 kg |
| ʻAno maʻi diabetes 2 | 10 mg | -2.2% | -9.5 kg |
| ʻAno maʻi diabetes 2 | 15 mg | -2.4% | -11.0 kg |
➡ Hoʻohālikelike ʻia me Semaglutide (1 mg: HbA1c -1.9%, Weight -6.0 kg), ua hōʻike ʻo Tirzepatide i nā hopena maikaʻi aʻe i ka mana glycemic a me ka poho kaumaha.
2. Nā ho'āʻo SURMOUNT (Obesity)
I nā poʻe maʻi momona me ka ʻole o ka maʻi diabetes, ua hōʻike ʻo Tirzepatide i ka maikaʻi o ka hoʻemi kaumaha.
| Kau | Avg. Hoemi Paona (72 pule) |
|---|---|
| 5 mg | -15% |
| 10 mg | -20% |
| 15 mg | -22.5% |
➡ No ka mea maʻi e kaupaona ana he 100 kg, hiki i ka Tirzepatide kiʻekiʻe ke hoʻemi i ke kaumaha a puni.22.5 kg.
Nā Pōmaikaʻi Nui
-
Mekani pālua: Ma waho aʻe o hoʻokahi agonists GLP-1.
-
ʻOi aku ka maikaʻi: Pono i ka glycemic control a me ke kaumaha.
-
Hoʻohana ākea: He kūpono no ka maʻi diabetes a me ka momona.
-
Kiʻekiʻe mākeke: Ke piʻi nei ka noi no nā kūlana lapaʻau obesity ʻo Tirzepatide ma ke ʻano he lāʻau blockbuster e hiki mai ana.
Mākeʻakaʻike
-
wānana ka nui o ka mākeke: Ma ka makahiki 2030, ua manaʻo ʻia ka mākeke lāʻau lapaʻau GLP-1 honua e ʻoi akuUSD 150 biliona, me Tirzepatide paha e hopu i ka mahele nui.
-
ʻĀina hoʻokūkū: ʻO ka hoʻokūkū nui ʻo Novo Nordisk's Semaglutide (Ozempic, Wegovy).
-
Pōmaikaʻi: Hōʻike nā hōʻike hōʻike hōʻike ʻo Tirzepatide i ka pohō kaumaha ʻoi aku ka maikaʻi ma mua o Semaglutide, e hoʻoikaika ana i kāna hoʻokūkū mākeke i ka mālama ʻana i ka momona.
Ka manawa hoʻouna: Sep-12-2025